Connect Biopharma Holdings Ltd. (CNTB)
2.07
+0.06
(+2.99%)
USD |
NASDAQ |
Sep 10, 16:00
2.07
0.00 (0.00%)
After-Hours: 20:00
Connect Biopharma Holdings Enterprise Value : 95.69M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 95.69M |
| September 08, 2026 | 89.39M |
| September 04, 2026 | 84.98M |
| September 03, 2026 | 90.65M |
| September 02, 2026 | 142.92M |
| September 01, 2026 | 117.73M |
| August 31, 2026 | 107.65M |
| August 28, 2026 | 109.54M |
| August 27, 2026 | 112.69M |
| August 26, 2026 | 115.84M |
| August 25, 2026 | 123.40M |
| August 24, 2026 | 113.95M |
| August 21, 2026 | 117.73M |
| August 20, 2026 | 112.69M |
| August 19, 2026 | 124.03M |
| August 18, 2026 | 122.14M |
| August 17, 2026 | 125.92M |
| August 14, 2026 | 129.69M |
| August 13, 2026 | 129.06M |
| August 12, 2026 | 115.84M |
| August 11, 2026 | 110.17M |
| August 10, 2026 | 104.50M |
| August 07, 2026 | 107.97M |
| August 06, 2026 | 107.02M |
| August 05, 2026 | 106.39M |
| Date | Value |
|---|---|
| August 04, 2026 | 99.47M |
| August 03, 2026 | 93.17M |
| July 31, 2026 | 96.32M |
| July 30, 2026 | 100.73M |
| July 29, 2026 | 98.21M |
| July 28, 2026 | 100.10M |
| July 27, 2026 | 101.36M |
| July 24, 2026 | 103.88M |
| July 23, 2026 | 107.65M |
| July 22, 2026 | 107.65M |
| July 21, 2026 | 108.28M |
| July 20, 2026 | 107.65M |
| July 17, 2026 | 118.99M |
| July 16, 2026 | 116.16M |
| July 15, 2026 | 122.14M |
| July 14, 2026 | 117.41M |
| July 13, 2026 | 111.43M |
| July 10, 2026 | 127.18M |
| July 09, 2026 | 136.62M |
| July 08, 2026 | 108.91M |
| July 07, 2026 | 108.28M |
| July 06, 2026 | 117.73M |
| July 02, 2026 | 124.03M |
| July 01, 2026 | 119.62M |
| June 30, 2026 | 118.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.44B |
| Oncolytics Biotech, Inc. | 95.42M |
| Sangamo Therapeutics, Inc. | 55.96M |
| Sarepta Therapeutics, Inc. | 2.583B |
| Anixa Biosciences, Inc. | 82.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.28M |
| Revenue (Quarterly) | 2.768M |
| Total Expenses (Quarterly) | 20.05M |
| EPS Diluted (Quarterly) | -0.2749 |
| Profit Margin (Quarterly) | -624.4% |
| Earnings Yield | -57.78% |
| Normalized Earnings Yield | -57.78 |